Topic inhibitor

News inhibitor

• Arteria will carry out regulatory preclinical studies in the field of postprandial hypertriglyceridemia following excellent initial results

  Arteria SA, a biopharmaceutical company focused on the development of new chemical entities for patients affected by metabolic diseases and Type II diabetes, announced that it has obtained highly promising results in preclinical non-regulatory studies for its AP-5258 molecule, an inhibitor of the CD more

• Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease

  Evotec AG and Roche AG announced that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec's MAO-B inhibitor in patients with Alzheimer's disease (AD).Under the terms of the agreement, Roche will pay Evotec an upfront fee of $10 million. Evotec more

• Pharming announces topline study results on prophylactic use of Ruconest in Hereditary Angioedema

  Pharming Group NV announced the results of its exploratory Phase II study on the safety and prophylactic effect of recombinant human C1 inhibitor ("rhC1INH") in patients with Hereditary Angioedema (HAE). The study is an open-label exploratory phase II study of the safety and prophylactic effect of more

White papers inhibitor

• Assessing Microbial Metabolism Using A Simple ‘Mix & Measure’ Oxygen Consumption Assay
  

  MitoXpress® from Luxcel Biosciences is a water-soluble oxygen-sensitive phosphorescent probe that facilitates microplate based analysis of microbial oxygen consumption. The microbial metabolism implications of treatments such as drug exposure, genetic manipulation or altered cultured conditions can be easily accessed using BMG LABTECH´s FLUOstar Omega microplate reader to read both growth and oxygen consumption in parallel more

• Altered Expression of Broad Range of Protease Genes in SH-SY5Y Neuroblastoma Cells after Bortezomib Exposure
  

  Neuroblastoma cell lines can be models for the responsiveness of neuroblastomas to chemotherapy-induced cell death as well as for the sensitivity of untransformed neuro-nal cells to toxic side-effects of chemotherapy. Both phenom-ena are relevant to neuroblastoma cells exposed to bortezomib, a proteasome inhibitor in clinical use. It has been shown previously that neuroblastoma cell lines are prone to undergo apoptosis when treated with bortezomib, but the precise molecular mechanism has not been revealed. In addition to this, peripheral neuropathy is the main side effect of chemotherapy that includes bortezomib more

• Amplicon Sequencing with the GS FLX Titanium Series: High Sensitivity Targeted Resequencing
  

  Amplicon sequencing with the Genome Sequencer FLX System has already enabled a wide variety of scientific discoveries, particularly in clinical research. The introduction of the GS FLX Titanium Chemistry and the release of the associated amplicon sequencing protocols will continue to expand applications, as more and longer amplicons increase the depth of analysis for detecting rare variants and improve coverage of gene loci more

Publications inhibitor

• Involvement of the L‐arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N‐palmitoyl‐ethanolamine in rats

  Abstract N‐palmitoyl‐ethanolamine (PEA) is an endogenous substance that was first identified in lipid tissue extracts. It has been classified as a CB2 receptor agonist. Exogenous PEA has the potential to become a valid treatment for neuropathic and inflammatory pain. In spite of the well‐demonstr more

• The miR‐17‐92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification

  Abstract Angiosarcomas (ASs) represent a heterogeneous group of malignant vascular tumors that may occur spontaneously as primary tumors or secondarily after radiation therapy or in the context of chronic lymphedema. Most secondary ASs have been associated with MYC oncogene amplification, whereas more

• The miR‐17‐92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification

  Abstract Angiosarcomas (ASs) represent a heterogeneous group of malignant vascular tumors that may occur spontaneously as primary tumors or secondarily after radiation therapy or in the context of chronic lymphedema. Most secondary ASs have been associated with MYC oncogene amplification, whereas more

Market studies inhibitor

• Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comp more

• Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market

  GBI Research, a leading business intelligence provider, has released its latest research “Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market”. The report provides in-depth analysis of t more

• Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global nasopharyngeal cancer therapeutics market. The more

Websites inhibitor